AR066971A1 - Derivado de 17beta-ciano-19-nor-androst-4-eno- su uso y medicamento que lo contiene - Google Patents
Derivado de 17beta-ciano-19-nor-androst-4-eno- su uso y medicamento que lo contieneInfo
- Publication number
- AR066971A1 AR066971A1 ARP080102499A ARP080102499A AR066971A1 AR 066971 A1 AR066971 A1 AR 066971A1 AR P080102499 A ARP080102499 A AR P080102499A AR P080102499 A ARP080102499 A AR P080102499A AR 066971 A1 AR066971 A1 AR 066971A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrogen
- group
- alkyl
- together form
- 17beta
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 abstract 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 208000017657 Menopausal disease Diseases 0.000 abstract 1
- 229940083712 aldosterone antagonist Drugs 0.000 abstract 1
- 230000001327 anti-mineralocorticoid effect Effects 0.000 abstract 1
- 238000006664 bond formation reaction Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 1
- 230000003152 gestagenic effect Effects 0.000 abstract 1
- 229910052736 halogen Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- -1 hydroxymethylene Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000002394 mineralocorticoid antagonist Substances 0.000 abstract 1
- 239000000583 progesterone congener Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
- C07J53/008—3 membered carbocyclic rings in position 15/16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
- C07J53/007—3 membered carbocyclic rings in position 6-7
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Toxicology (AREA)
- Pregnancy & Childbirth (AREA)
- Epidemiology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Los derivados de 17beta-ciano-19-nor-androst-4-eno reivindicados presentan actividad gestágena. Tienen la formula química general 1, en la cual Z se selecciona del grupo que comprende O, dos átomos de hidrogeno, NOR y NNHSO2R, donde R es hidrogeno o alquilo C1-4, R4 es hidrogeno o halogeno, además o bien: R6a, R6b juntos forman metileno o 1,2-etanodiilo o R6a es hidrogeno y R6b se selecciona del grupo que comprende hidrogeno, metilo e hidroximetileno, y R7 se selecciona del grupo que comprende hidrogeno, alquilo C1-4, alquenilo C2-3 y ciclopropilo, o R6a es hidrogeno y R6b y R7 juntos forman metileno o se omiten por formacion de un enlace doble entre C6 y C7; R9, R10 son H, o se omiten por formacion de un enlace doble entre C9 y C10; R15, R16 son H o juntos forman metileno; R17 se selecciona del grupo que comprende hidrogeno, alquilo C1-4 y alilo, donde al menos uno de los sustituyentes R4, R6a, R6b, R7, R15, R16 y R17 no es H o R6b y R7 se omiten por formacion de un enlace doble entre C6 y C7, y sus solvatos, hidratos, estereoisomeros, diastereomeros, enantiomeros y sales. También este compuesto se utiliza en un medicamento para el tratamiento de trastornos pre-, peri- y post-menopáusicos y es efectivo como gestágeno y antimineralocorticoide.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007027637A DE102007027637A1 (de) | 2007-06-12 | 2007-06-12 | 17ß-Cyano-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066971A1 true AR066971A1 (es) | 2009-09-23 |
Family
ID=39986163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102499A AR066971A1 (es) | 2007-06-12 | 2008-06-12 | Derivado de 17beta-ciano-19-nor-androst-4-eno- su uso y medicamento que lo contiene |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8207150B2 (es) |
| EP (1) | EP2170925B1 (es) |
| JP (1) | JP2010529153A (es) |
| KR (1) | KR20100028554A (es) |
| CN (1) | CN101679478A (es) |
| AR (1) | AR066971A1 (es) |
| AU (1) | AU2008261278A1 (es) |
| BR (1) | BRPI0813937A2 (es) |
| CA (1) | CA2690959A1 (es) |
| DE (1) | DE102007027637A1 (es) |
| ES (1) | ES2397996T3 (es) |
| IL (1) | IL202359A0 (es) |
| MX (1) | MX2009013629A (es) |
| PA (1) | PA8784401A1 (es) |
| PE (1) | PE20090822A1 (es) |
| RU (1) | RU2010100331A (es) |
| TW (1) | TW200909444A (es) |
| UY (1) | UY31146A1 (es) |
| WO (1) | WO2008151746A2 (es) |
| ZA (1) | ZA201000187B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007027635A1 (de) * | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17ß-Cyano-19-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| DE102007027637A1 (de) | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17ß-Cyano-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| WO2010066355A1 (de) * | 2008-12-12 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | VERWENDUNG VON 17β- CYANO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG |
| WO2012059594A1 (en) | 2010-11-04 | 2012-05-10 | Bayer Pharma Aktiengesellschaft | Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity |
| CN104530165A (zh) * | 2014-12-10 | 2015-04-22 | 浙江仙琚制药股份有限公司 | 制备4,9-双烯物的方法 |
| CN105085596A (zh) * | 2015-08-18 | 2015-11-25 | 湖北竹溪人福药业有限责任公司 | 一种羧酸黄体酮的制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3043833A (en) * | 1961-07-14 | 1962-07-10 | Ormonoterapia Richter Spa | 17-cyanohydrin of 19-nor androstenedione and 3-derivatives thereof |
| DE1183500B (de) | 1962-10-12 | 1964-12-17 | Schering Ag | Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe |
| US3579509A (en) * | 1965-06-21 | 1971-05-18 | Smith Kline French Lab | Process and 6-beta-substituted ethyl intermediates for preparing 6,6-ethylene-3-keto-delta**4 steroids |
| GB1089945A (en) * | 1965-09-23 | 1967-11-08 | British Drug Houses Ltd | Steroidal-6-spirocyclopropyl-4-en-3-ones |
| CH538462A (de) * | 1970-10-07 | 1973-06-30 | Ciba Geigy Ag | Ein neues Verfahren zur Herstellung von 6a-Methyl-19-nor-pregnenen |
| US3705179A (en) | 1971-03-15 | 1972-12-05 | American Home Prod | Antiandrogenic steroids |
| FR2139708B1 (es) * | 1971-06-01 | 1974-08-23 | Roussel Uclaf | |
| BE795241A (fr) | 1972-02-11 | 1973-08-09 | Schering Ag | 15alpha, 16alpha-methylene-4-oestren-17beta-ols-methylenz-4-oestren-17beta-ols et leur procede de preparation |
| DE2456068A1 (de) | 1974-11-23 | 1976-08-12 | Schering Ag | Verfahren zur herstellung von oestren3,17-dion-derivaten |
| NL7701384A (nl) | 1977-02-10 | 1978-08-14 | Akzo Nv | Werkwijze voor het bereiden van nieuwe steroiden van de oestraanreeks. |
| DE2922500A1 (de) | 1979-05-31 | 1980-12-04 | Schering Ag | 6 beta .7 beta |
| US4252800A (en) * | 1979-10-05 | 1981-02-24 | United States Of America | 7α-methylnorethindrone enanthate and its use in long term suppression of fertility in female mammals |
| US4512986A (en) * | 1983-07-26 | 1985-04-23 | Research Triangle Institute | Progrestationally active steroids |
| US4544554A (en) * | 1983-09-26 | 1985-10-01 | Ortho Pharmaceutical Corporation | Triphasic oral contraceptive |
| DE3402329A1 (de) | 1984-01-20 | 1985-08-01 | Schering AG, 1000 Berlin und 4709 Bergkamen | 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
| DD281394A5 (de) * | 1984-12-10 | 1990-08-08 | Jenapharm Veb | Verfahren zur herstellung von steroid-c-17 alpha-carbonitrilen |
| DD281393A5 (de) * | 1984-12-10 | 1990-08-08 | Jenapharm Veb | Verfahren zur herstellung von steroid-c-17 beta-carbonitrilen |
| DE4344462C2 (de) * | 1993-12-22 | 1996-02-01 | Schering Ag | Zusammensetzung für die Empfängnisverhütung |
| EP0785211A1 (en) * | 1996-01-22 | 1997-07-23 | Laboratoire Theramex | New substituted 19-nor-pregnane derivatives |
| DE19651000A1 (de) | 1996-12-01 | 1998-06-04 | Schering Ag | Oxyiminopregnancarbolactone |
| DE102004063864A1 (de) | 2004-12-30 | 2006-07-13 | Schering Ag | 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate |
| DE102007027637A1 (de) | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17ß-Cyano-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
-
2007
- 2007-06-12 DE DE102007027637A patent/DE102007027637A1/de not_active Withdrawn
-
2008
- 2008-06-04 AU AU2008261278A patent/AU2008261278A1/en not_active Abandoned
- 2008-06-04 RU RU2010100331/04A patent/RU2010100331A/ru not_active Application Discontinuation
- 2008-06-04 WO PCT/EP2008/004429 patent/WO2008151746A2/de active Application Filing
- 2008-06-04 KR KR1020097025930A patent/KR20100028554A/ko not_active Application Discontinuation
- 2008-06-04 BR BRPI0813937-7A2A patent/BRPI0813937A2/pt not_active Application Discontinuation
- 2008-06-04 ES ES08758990T patent/ES2397996T3/es active Active
- 2008-06-04 MX MX2009013629A patent/MX2009013629A/es not_active Application Discontinuation
- 2008-06-04 CN CN200880020020A patent/CN101679478A/zh active Pending
- 2008-06-04 EP EP08758990A patent/EP2170925B1/de not_active Not-in-force
- 2008-06-04 JP JP2010511526A patent/JP2010529153A/ja active Pending
- 2008-06-04 CA CA2690959A patent/CA2690959A1/en not_active Abandoned
- 2008-06-11 UY UY31146A patent/UY31146A1/es not_active Application Discontinuation
- 2008-06-11 TW TW097121802A patent/TW200909444A/zh unknown
- 2008-06-11 PA PA20088784401A patent/PA8784401A1/es unknown
- 2008-06-11 PE PE2008000994A patent/PE20090822A1/es not_active Application Discontinuation
- 2008-06-11 US US12/137,111 patent/US8207150B2/en not_active Expired - Fee Related
- 2008-06-12 AR ARP080102499A patent/AR066971A1/es unknown
-
2009
- 2009-11-26 IL IL202359A patent/IL202359A0/en unknown
-
2010
- 2010-01-11 ZA ZA2010/00187A patent/ZA201000187B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2397996T3 (es) | 2013-03-13 |
| DE102007027637A1 (de) | 2008-12-18 |
| WO2008151746A3 (de) | 2009-03-12 |
| IL202359A0 (en) | 2010-06-30 |
| CN101679478A (zh) | 2010-03-24 |
| CA2690959A1 (en) | 2008-12-18 |
| BRPI0813937A2 (pt) | 2014-12-30 |
| US8207150B2 (en) | 2012-06-26 |
| AU2008261278A1 (en) | 2008-12-18 |
| KR20100028554A (ko) | 2010-03-12 |
| RU2010100331A (ru) | 2011-07-20 |
| EP2170925A2 (de) | 2010-04-07 |
| JP2010529153A (ja) | 2010-08-26 |
| MX2009013629A (es) | 2010-01-20 |
| PE20090822A1 (es) | 2009-07-25 |
| TW200909444A (en) | 2009-03-01 |
| UY31146A1 (es) | 2009-01-30 |
| EP2170925B1 (de) | 2012-10-24 |
| PA8784401A1 (es) | 2009-01-23 |
| US20090048217A1 (en) | 2009-02-19 |
| ZA201000187B (en) | 2011-03-30 |
| WO2008151746A2 (de) | 2008-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066970A1 (es) | Derivado de 17 beta-ciano-18a-homo-19-nor-androst-4- eno, su uso y medicamento que lo contiene | |
| AR066971A1 (es) | Derivado de 17beta-ciano-19-nor-androst-4-eno- su uso y medicamento que lo contiene | |
| AR060050A1 (es) | Compuestos moduladores del receptor de s1p y uso de los mismos | |
| AR072787A1 (es) | Compuestos y composiciones como inhibidores de cinasa | |
| AR049388A1 (es) | Heterociclos como inhibidores de aldosterona sintasa | |
| AR083169A1 (es) | Compuestos para tratar enfermedades neurodegenerativas | |
| AR088061A1 (es) | Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso | |
| BR112012018865A2 (pt) | naftiridinas substituídas e seu uso como inibidores de quinase syk | |
| AR056025A1 (es) | Compuestos de imidazol sustituidos como inhibidores de ksp | |
| AR036044A1 (es) | Compuestos piranoindazoles, composiciones farmaceuticas y su uso para la manufactura de un medicamento para el tratamiento del glaucoma | |
| AR078776A1 (es) | Derivados de (1,1,1,3,3,3-hexafluoro-2-hidroxipropan-2-il)-fenilo | |
| AR067542A1 (es) | Compuestos macrociclicos de indol utiles para el tratamiento de hepatitis c | |
| PH12017501655A1 (en) | Morphinan derivative | |
| CO5570696A2 (es) | 1-amino-alquilciclohexanos insaturados como antagonistas de los receptores nmda, 5ht3 y nicotinico neuronal | |
| AR052332A1 (es) | Derivados de benzdioxanpiperazina con una afinidad combinada para receptores de dopamina-d2 y sitios de reabsorcion de serotonina, composiciones farmaceuticas que los contienen y su empleo como medicamentos para el tratamiento de enfermedades del snc | |
| AR047337A1 (es) | Ligandos de los receptores de acetilcolina nicotinicos | |
| AR052258A1 (es) | Derivados de fenilpiperazinas con una afinidad combinada para receptores de dopamina - d2 y sitios de reabsorcion de serotonina, composiciones farmaceuticas que los contienen y su empleo como medicamentos para el tratamiento de enfermedades del sistema nervioso central. | |
| AR069700A1 (es) | Derivados de azetidina,composiciones farmaceuticas que los comprenden, metodo de preparacion, intermediarios de sintesis,y usos de los mismos en el tratamiento o prevencion de trastornos psiquiatricos , del sistema inmune y gastrointestinales, entre otros. | |
| ECSP10010315A (es) | Derivados de 19-nor-esteroide que tiene un grupo 15 ,16 -metileno y un anillo de 17,17-espirolactona saturado, su uso y medicamentos que los comprenden | |
| UY27544A1 (es) | Derivados de piperazina desestabilizantes del receptor de andrógenos | |
| AR029458A1 (es) | Compuestos activos en el receptor de glucocorticoide | |
| WO2008152112A3 (de) | 17ß-CYANO-19-ANDROST-4-EN-DERIVAT, DESSEN VERWENDUNG UND DAS DERIVAT ENTHALTENDE ARZNEIMITTEL | |
| AR069965A1 (es) | Derivado de (gamma)-lactona de esteroide de acido 15, 16 -metilen-17-hidroxi-19-nor-21-carboxilico, su uso para preparar un medicamento que lo contiene y medicamento que contiene al compuesto | |
| AR085816A1 (es) | Derivados de isoxazolidina | |
| PE20091181A1 (es) | Derivado 15,16-metilen-17-(1'-propenil)-17-3' -oxidoestra-4-en-3-ona, su uso y medicamento que lo contiene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |